196 related articles for article (PubMed ID: 16676088)
1. Genetic background and inhibitors in previously untreated or minimally treated young patients with severe haemophilia A treated with sucrose-formulated recombinant factor VIII.
Oldenburg J; Ivaskevicius V; Schröder J; Müller CR; Ganguly A
Thromb Haemost; 2006 May; 95(5):903-5. PubMed ID: 16676088
[No Abstract] [Full Text] [Related]
2. Factor VIII haplotypes in severe hemophilia A patients in India.
Pinto P; Ghosh K; Shetty S
Ann Hematol; 2013 Jul; 92(7):999-1000. PubMed ID: 23262994
[No Abstract] [Full Text] [Related]
3. How do some haemophiliacs develop inhibitors?
Vermylen J
Haemophilia; 1998 Jul; 4(4):538-42. PubMed ID: 9873790
[TBL] [Abstract][Full Text] [Related]
4. The genetic basis of inhibitor development in haemophilia A.
Tuddenham EG; McVey JH
Haemophilia; 1998 Jul; 4(4):543-5. PubMed ID: 9873791
[TBL] [Abstract][Full Text] [Related]
5. Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A.
Mauser-Bunschoten EP; van der Bom JG; Bongers M; Twijnstra M; Roosendaal G; Fischer K; van den Berg HM
Haemophilia; 2001 Jul; 7(4):364-8. PubMed ID: 11442640
[TBL] [Abstract][Full Text] [Related]
6. Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.
Scharrer I; Bray GL; Neutzling O
Haemophilia; 1999 May; 5(3):145-54. PubMed ID: 10444280
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products.
Rota M; Cortesi PA; Steinitz-Trost KN; Reininger AJ; Gringeri A; Mantovani LG
Blood Coagul Fibrinolysis; 2017 Dec; 28(8):627-637. PubMed ID: 28678027
[TBL] [Abstract][Full Text] [Related]
8. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation.
Kreuz W; Gill JC; Rothschild C; Manco-Johnson MJ; Lusher JM; Kellermann E; Gorina E; Larson PJ;
Thromb Haemost; 2005 Mar; 93(3):457-67. PubMed ID: 15735795
[TBL] [Abstract][Full Text] [Related]
9. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
Gouw SC; Van Der Bom JG; Van Den Berg HM; Zewald RA; Ploos Van Amstel JK; Mauser-Bunschoten EP
Haemophilia; 2011 Mar; 17(2):275-81. PubMed ID: 21070499
[TBL] [Abstract][Full Text] [Related]
10. The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom.
Mathias MC; Collins PW; Palmer BP; Chalmers E; Alamelu J; Richards M; Will A; Hay CRM;
Haemophilia; 2018 Nov; 24(6):896-901. PubMed ID: 30004617
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor development and management in three non-severe haemophilia A patients with T295A variant.
Ivaskevicius V; Goldmann G; Horneff S; Marquardt N; Klein C; Albert T; Zeitler H; Oldenburg J
Hamostaseologie; 2014; 34 Suppl 1():S9-12. PubMed ID: 25382774
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors in childhood hemophilia A: genetic and treatment-related risk factors for development and eradication.
DiMichele DM
Pediatr Blood Cancer; 2013; 60 Suppl 1():S30-3. PubMed ID: 23109404
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of factor VIII in hemophilia.
Lacroix-Desmazes S; Dimitrov JD; Repesse Y
N Engl J Med; 2009 Jul; 361(3):308; author reply 310. PubMed ID: 19605840
[No Abstract] [Full Text] [Related]
15. Inhibitor incidence in haemophilia A under exclusive use of a third-generation recombinant factor VIII concentrate: results of the HEMFIL Cohort Study.
Jardim LL; van der Bom J; Brommonschenkel CC; Gouw SC; Rezende SM;
Br J Haematol; 2019 Jul; 186(1):152-155. PubMed ID: 30556277
[No Abstract] [Full Text] [Related]
16. The use of agents that by-pass factor VIII inhibitors in patients with haemophilia.
Roberts HR
Vox Sang; 1999; 77 Suppl 1():38-41. PubMed ID: 10529686
[No Abstract] [Full Text] [Related]
17. Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A.
van Helden PM; Kaijen PH; Mauser-Bunschoten EP; Fischer K; van den Berg HM; Voorberg J
Haemophilia; 2010 Nov; 16(6):892-901. PubMed ID: 20491952
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593-->Cys substitution.
van den Brink EN; Timmermans SM; Turenhout EA; Bank CM; Fijnvandraat K; Voorberg J; Peters M
Thromb Haemost; 1999 May; 81(5):723-6. PubMed ID: 10365744
[TBL] [Abstract][Full Text] [Related]
19. Cumulative analysis of inhibitor formation in patients with haemophilia A treated with sucrose-formulated recombinant factor VIII.
Bajwa N; Enriquez MM; Gorina E; Lemm G
Haemophilia; 2009 Mar; 15(2):597-600. PubMed ID: 19187195
[No Abstract] [Full Text] [Related]
20. Previously untreated patients and recombinant factor VIII concentrate studies.
Pasi KJ
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S29-32. PubMed ID: 9351534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
